通过循环中介抑制核动素聚合的加剧性性结肠炎
William W Du1,2, Chi Zhou1,2,3,4,5, Hui Yang6
1Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
Research (Washington, D.C.)
|August 26, 2024
概括
循环RNA circNlgn通过产生Nlgn173蛋白质促进结肠炎,该蛋白质破坏结肠上皮细胞中的actin聚合. 抑制cirNlgn或Nlgn173可能为性结肠炎提供新的治疗方法.
科学领域:
- 胃肠病学 胃肠病学
- 分子生物学分子生物学
- 细胞生物学 细胞生物学
背景情况:
- 大肠炎是一种慢性肠道疾病,原因不明.
- 大肠内的损伤是结肠炎的特征.
- 循环RNA越来越多地被认为是它们在疾病发病过程中的作用.
研究的目的:
- 研究循环RNA在结肠炎发展中的作用.
- 阐明circNlgn影响大肠炎的分子机制.
- 探索cirNlgn及其编码蛋白作为大肠炎的潜在治疗点.
主要方法:
- 在大肠炎患者中分析循环水平.
- 产生和研究表达circNlgn的转基因小鼠.
- 在结肠上皮细胞中研究Nlgn173蛋白的功能.
- 评估行为因动力学,细胞循环,细胞亡和增殖.
- 针对cirNlgn和Nlgn173.3的治疗策略的评估.
主要成果:
- 大肠炎患者表现出明显更高的循环水平.
- 转基因小鼠与circNlgn显示大肠炎的易感性增加.
- 由circNlgn编码的蛋白质异型Nlgn173通过抑制Arp2/3复合体来破坏核活性质聚合.
- Nlgn173增强了核活性蛋白的酸化,减少了它与Arp2/3的相互作用,并减少了丝状活性蛋白.
- 这些变化导致细胞增殖抑制,细胞亡增加和结肠炎恶化.
- 沉默循环或抑制Nlgn173改善了体内大肠炎的结果.
- 核活性蛋白聚合与PIAS3表达有关,调节STAT3和NF-κB信号传递.
结论:
- 循环RNA circNlgn,通过其编码的蛋白质Nlgn173,通过破坏结肠上皮细胞动力学来驱动结肠炎的发病.
- 针对cirNlgn或Nlgn173介导的核活性失调,为性结肠炎提供了一个有前途的治疗策略.
- 调节核激素聚合和相关信号通路为急性性结肠炎的临床干预提供了一个新的途径.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
130
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
130
Inflammatory Bowel Disease I: Ulcerative Colitis
159
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
159
Inflammatory Bowel Disease II: Crohn's Disease
205
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
205
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
145
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
145
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
120
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
120
Inflammatory Bowel Disease V: Surgical Management
133
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
133


